ValiRx plc (VAL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ValiRx plc (VAL) has a cash flow conversion efficiency ratio of -0.179x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£-700.73K ≈ $-941.02K USD) by net assets (£3.92 Million ≈ $5.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is ValiRx plc's balance sheet to measure how much of total assets are equity-financed.
ValiRx plc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how ValiRx plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ValiRx plc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
ValiRx plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ValiRx plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZEUS Resources Ltd
AU:ZEU
|
-0.114x |
|
Elite Education Group International Ltd
NASDAQ:EEIQ
|
-0.045x |
|
TTL Beteiligungs- und Grundbesitz-AG
F:TTO
|
0.226x |
|
Devernois SA
PA:ALDEV
|
0.100x |
|
Commander Resources Ltd
V:CMD
|
-0.123x |
|
Aeeris Ltd
AU:AER
|
0.108x |
|
Ecofin Global Utilities and Infrastructure Trust plc
LSE:EGL
|
0.000x |
|
Kmc Properties ASA
OL:KMCP
|
0.039x |
Annual Cash Flow Conversion Efficiency for ValiRx plc (2001–2024)
The table below shows the annual cash flow conversion efficiency of ValiRx plc from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see ValiRx plc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | £3.92 Million ≈ $5.26 Million |
£-1.58 Million ≈ $-2.13 Million |
-0.405x | +33.68% |
| 2023-12-31 | £2.90 Million ≈ $3.90 Million |
£-1.77 Million ≈ $-2.38 Million |
-0.610x | -36.39% |
| 2022-12-31 | £3.83 Million ≈ $5.14 Million |
£-1.71 Million ≈ $-2.30 Million |
-0.447x | -21.21% |
| 2021-12-31 | £3.41 Million ≈ $4.59 Million |
£-1.26 Million ≈ $-1.69 Million |
-0.369x | +8.12% |
| 2020-12-31 | £4.76 Million ≈ $6.39 Million |
£-1.91 Million ≈ $-2.57 Million |
-0.402x | +33.42% |
| 2019-12-31 | £2.22 Million ≈ $2.99 Million |
£-1.34 Million ≈ $-1.80 Million |
-0.604x | +45.45% |
| 2018-12-31 | £3.03 Million ≈ $4.07 Million |
£-3.35 Million ≈ $-4.50 Million |
-1.106x | -48.34% |
| 2017-12-31 | £3.15 Million ≈ $4.23 Million |
£-2.35 Million ≈ $-3.16 Million |
-0.746x | +58.08% |
| 2016-12-31 | £2.37 Million ≈ $3.18 Million |
£-4.22 Million ≈ $-5.66 Million |
-1.779x | -211.40% |
| 2015-12-31 | £4.53 Million ≈ $6.09 Million |
£-2.59 Million ≈ $-3.48 Million |
-0.571x | +47.02% |
| 2014-12-31 | £2.79 Million ≈ $3.74 Million |
£-3.01 Million ≈ $-4.04 Million |
-1.079x | -68.52% |
| 2013-12-31 | £3.23 Million ≈ $4.34 Million |
£-2.07 Million ≈ $-2.78 Million |
-0.640x | -62.79% |
| 2012-12-31 | £5.04 Million ≈ $6.76 Million |
£-1.98 Million ≈ $-2.66 Million |
-0.393x | -19.06% |
| 2011-12-31 | £4.42 Million ≈ $5.94 Million |
£-1.46 Million ≈ $-1.96 Million |
-0.330x | -32.96% |
| 2010-12-31 | £2.00 Million ≈ $2.68 Million |
£-496.00K ≈ $-666.08K |
-0.248x | +75.67% |
| 2009-12-31 | £907.00K ≈ $1.22 Million |
£-926.00K ≈ $-1.24 Million |
-1.021x | -76.42% |
| 2008-12-31 | £1.37 Million ≈ $1.84 Million |
£-794.00K ≈ $-1.07 Million |
-0.579x | -15.19% |
| 2007-12-31 | £1.67 Million ≈ $2.24 Million |
£-839.00K ≈ $-1.13 Million |
-0.502x | -2848.55% |
| 2006-12-31 | £2.69 Million ≈ $3.61 Million |
£-45.77K ≈ $-61.46K |
-0.017x | +95.01% |
| 2006-03-31 | £161.00K ≈ $216.21K |
£-55.00K ≈ $-73.86K |
-0.342x | -210.08% |
| 2005-12-31 | £-203.00K ≈ $-272.61K |
£-63.00K ≈ $-84.60K |
0.310x | -90.48% |
| 2004-12-31 | £-69.00K ≈ $-92.66K |
£-225.00K ≈ $-302.15K |
3.261x | +195.24% |
| 2003-12-31 | £67.00K ≈ $89.97K |
£74.00K ≈ $99.38K |
1.104x | +108.81% |
| 2002-12-31 | £-141.00K ≈ $-189.35K |
£1.77 Million ≈ $2.37 Million |
-12.539x | -759.53% |
| 2001-12-31 | £1.00 Million ≈ $1.35 Million |
£1.91 Million ≈ $2.56 Million |
1.901x | -- |
About ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more